Litigation Details for AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2014-05-23
Court	District Court, D. Delaware	Date Terminated	2017-02-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Parties	ACTAVIS INC.
Patents	6,395,767; 7,951,400; 8,628,799; RE44,186
Attorneys	Daniel J. Brown
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2014-05-23	1		product, prior to expiration of U.S. Patent No. 7,951,400 (“the ’400 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … THE ’400 PATENT 14. On May 31, 2011, the U.S. Patent and Trademark Office …copy of the ’400 patent is attached hereto as Exhibit A. The claims of the ’400 patent are valid and …includes ONGLYZA® together with the’400 patent and U.S. Patent No. RE44,186, which covers the composition	External link to document
2015-02-17	138		Infringement and Invalidity Contentions for U.S. Patent Nos. 7,951,400 and 8,628,799 by Actavis Laboratories FL…2014 2 February 2017 1:14-cv-00664 830 Patent Defendant District Court, D. Delaware	External link to document
2015-04-13	155		Dismissal of Formulation Patent Claims Concerning U.S. Patent No. 7,951,400 Between AstraZeneca and Aurobindo…2014 2 February 2017 1:14-cv-00664 830 Patent Defendant District Court, D. Delaware	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document